Patents by Inventor Viola LAM

Viola LAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NR4A-deficient cells expressing c-Jun and uses thereof
    Patent number: 12679879
    Abstract: The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: July 14, 2026
    Assignee: Lyell Immunopharma, Inc.
    Inventors: Viola Lam, Rachel Christina Lynn
  • POLYNUCLEOTIDES TARGETING NR4A3 AND USES THEREOF
    Publication number: 20260083846
    Abstract: The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and/or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a region within the NR4A3 gene. The present disclosure also provides the use of such polynucleotides to treat various diseases or disorders.
    Type: Application
    Filed: May 19, 2023
    Publication date: March 26, 2026
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Viola LAM, Rachel Christina LYNN
  • NR4A3-DEFICIENT IMMUNE CELLS AND USES THEREOF
    Publication number: 20240374725
    Abstract: The preset disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to express reduced levels of NR4A3 gene and/or NR4A3 protein. Also provided are modified cells, e.g., immune cell, which have been modified to express reduced levels of NR4A3 gene and/or NR4A3 protein. Reducing levels of NR4A3 gene and/or NR4A3 protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
    Type: Application
    Filed: May 27, 2022
    Publication date: November 14, 2024
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Viola LAM, Rachel Christina LYNN
  • NR4A-DEFICIENT CELLS EXPRESSING C-JUN AND USES THEREOF
    Publication number: 20230052243
    Abstract: The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
    Type: Application
    Filed: June 1, 2022
    Publication date: February 16, 2023
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Viola LAM, Rachel Christina LYNN